Product
GFH009
3 clinical trials
3 indications
Indication
Peripheral T-cell LymphomaIndication
Diffuse Large B-cell LymphomaIndication
Hematologic MalignanciesClinical trial
A Phase Ib/II, Multicentre, Open-label Study to Assess the Efficacy, Safety/ Tolerability and Pharmacokinetic of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase Ib/II, Multicenter, Open-label, Single-arm Study to Assess the Safety and Efficacy of GFH009 in Combination With Zanubrutinib in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2024-06-30